BET1L Knockout HT29 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma epithelial cell line, with disruption of the BET1L gene. This polyclonal knockout model provides a heterogeneous, gene-edited cell pool in which BET1L function is abrogated across the population, enabling loss-of-function studies without clonal selection artifacts. The product is designed for researchers investigating the roles of BET1L in vesicular transport, Golgi homeostasis, and cancer cell biology within a physiologically relevant intestinal epithelial background. By eliminating BET1L expression through CRISPR/Cas9-mediated gene disruption, these cells serve as a versatile tool for dissecting SNARE-dependent membrane fusion events and their downstream consequences in colorectal adenocarcinoma.
The parental HT29 cell line was established from a primary colon adenocarcinoma of a 44-year-old female and is widely employed as a model for colorectal adenocarcinoma. HT29 cells exhibit an epithelial morphology and retain the capacity for intestinal differentiation under appropriate culture conditions, making them valuable for studies on intestinal epithelial polarity, barrier function, and permeability. This cell line is extensively utilized in cancer research and drug development, particularly for evaluating chemotherapeutic agents, studying oncogenic signaling pathways, and probing mechanisms of mucosal homeostasis. The HT29 background thus provides a clinically relevant context for exploring gene functions pertinent to colorectal tumorigenesis and normal epithelial physiology.
BET1L encodes a SNARE (soluble N-ethylmaleimide?Csensitive factor attachment protein receptor) protein that functions as a key mediator of anterograde transport from the endoplasmic reticulum to the Golgi apparatus. It forms a fusogenic SNARE complex by interacting with syntaxin-5, GOSR2 (membrin), and Sec22b, thereby facilitating the fusion of COPII vesicles with the cis-Golgi membrane. This complex is further regulated by Rab GTPases such as Rab1 and tethering factors including p115, GM130, and giantin. Upstream regulators of BET1L include endoplasmic reticulum stress sensors like ATF6 and XBP1, growth factor signaling cascades, and cell cycle regulatory proteins, linking vesicle trafficking to broader cellular stress responses. Downstream, BET1L-dependent transport influences the processing and secretion of numerous proteins, including secreted factors, membrane receptors, and Golgi-resident enzymes, thereby impacting glycosylation and extracellular signaling.
In the HT29 colorectal adenocarcinoma context, disruption of BET1L is expected to perturb ER-to-Golgi trafficking, leading to altered Golgi morphology, impaired protein glycosylation, and defective secretion. These changes may affect the presentation of cell surface receptors, the secretion of tumor-promoting factors, and the integrity of the intestinal epithelial barrier. Since colorectal cancer cells often upregulate secretory pathways to support proliferation, invasion, and immune modulation, BET1L knockout provides a targeted approach to dissect the contribution of SNARE-mediated trafficking to malignancy. This model is therefore highly relevant for investigating how vesicular transport defects influence tumor cell behavior, differentiation, and responses to therapeutic interventions.
Research applications for these polyclonal knockout cells span a wide spectrum of experimental approaches. The model is well suited for studying the mechanistic role of BET1L in colorectal cancer vesicle trafficking and for examining the secretory pathway during intestinal epithelial differentiation. Typical assays include Western blotting for SNARE components, immunofluorescence microscopy to assess Golgi morphology, and secretion assays using reporters such as Gaussia luciferase. Additionally, the cells enable RT-qPCR profiling of trafficking genes, cell viability and migration/invasion assays under conditions of impaired secretion, electron microscopy to visualize vesicle accumulation, co-immunoprecipitation of the SNARE complex, pulse-chase analysis of protein secretion kinetics, and drug sensitivity screens to identify trafficking inhibitors. For further information, please contact Ascent Research.
